NYKD Share Price Performance
NOK 2.53
-0.13 (-4.89%)
Price NOK 2.53
Share Pricen/a
Nykode Therapeutics AS Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
NYKD Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Nykode Therapeutics AS Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 25, 2026
- -0.034
- 100.00%
- -149.77%
- 0%
About NYKD
- Founded
- 2006
- Employees
- 62
- CEO
- WebsiteView website
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
